Mini Pharmacy Enterprises Inc. has been acquired by Angeles Equity Partners, LLC
The owners of Mini Pharmacy Enterprises Inc. have sold the company to Angeles Equity Partners, LLC.
Mini Pharmacy Enterprises provides healthcare devices and prescription pharmaceuticals. The company offers diabetic supplies, glucose monitors, general prescriptions, nutritional formulas and durable medical equipment to suffering patients by being committed to improving patient outcomes and providing a personalized approach to professional diabetes management.
Angeles Equity Partners is a private equity investment firm which specializes in turnarounds, recapitalization, industry consolidation, buyouts, growth capital and later stage investments. The firm prefers to invest in companies based in North America operating in the packaging, electrical components, distribution, transportation, industrial and manufacturing sectors. It was founded in 2014 and is based in Los Angeles, California.
Oaklins' team in Los Angeles aced as the exclusive financial advisor to the shareholders of Mini Pharmacy Enterprises.
Talk to the deal team
Gary S. Rabishaw
Oaklins Intrepid
Kyle Kearney
Oaklins Intrepid
Related deals
Top Systems teams up with Holland Capital to create the premier Dutch battery-based solutions provider
Holland Capital, a Netherlands-based private equity firm, has acquired a stake in Top Systems, a leading provider of complete battery-based power solutions, with a unique value-added services proposition.
Learn moreInfotreasury has been sold to Matera
Matera, a leading banking software company with world-class instant payments and core banking solutions, has acquired Infotreasury.
Learn moreThrive Freeze Dry has successfully sealed the acquisition deal with Paradiesfrucht GmbH
Paradiesfrucht GmbH, a gobal freeze dryer of fruits, fruit preparations, drops, powders and granulates, has been acquired by Thrive Freeze Dry (Thrive), a portfolio company of Entrepreneurial Equity Partners (e2p) and Mubadala Capital. The transaction is expected to close in 2024, subject to customary closing conditions, including antitrust approval.
Learn more